المؤلفون: Ikuno Y; Osaka University Medical School, Osaka, Japan. Electronic address: yasushi.ikuno@gmail.com., Ohno-Matsui K; Osaka University Medical School, Osaka, Japan., Wong TY; Osaka University Medical School, Osaka, Japan., Korobelnik JF; Osaka University Medical School, Osaka, Japan., Vitti R; Osaka University Medical School, Osaka, Japan., Li T; Osaka University Medical School, Osaka, Japan., Stemper B; Osaka University Medical School, Osaka, Japan., Asmus F; Osaka University Medical School, Osaka, Japan., Zeitz O; Osaka University Medical School, Osaka, Japan., Ishibashi T; Osaka University Medical School, Osaka, Japan.

المصدر: Ophthalmology [Ophthalmology] 2016 Feb; Vol. 123 (2), pp. e17-e18.

نوع المنشور: Letter; Comment

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print Cited Medium: Internet ISSN: 1549-4713 (Electronic) Linking ISSN: 01616420 NLM ISO Abbreviation: Ophthalmology Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors/*therapeutic use , Choroidal Neovascularization/*drug therapy , Myopia, Degenerative/*drug therapy , Receptors, Vascular Endothelial Growth Factor/*therapeutic use , Recombinant Fusion Proteins/*therapeutic use, Female ; Humans ; Male

المؤلفون: Ikuno Y; Department of Ophthalmology, Osaka University School of Medicine, Osaka, Japan., Ohno-Matsui K; Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, Tokyo, Japan., Wong TY; Singapore Eye Research Institute, Singapore National Eye Center, Duke-NUS Graduate Medical School, National University of Singapore, Singapore., Korobelnik JF; Service d'ophtalmologie, Hopital Pellegrin-CHU de Bordeaux, Bordeaux, France; Université Bordeaux Segalen, Bordeaux, France; INSERM, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France., Vitti R; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Li T; Bayer HealthCare Pharmaceuticals, Beijing, China., Stemper B; Bayer HealthCare Pharmaceuticals, Berlin, Germany; Department of Neurology, University of Erlangen-Nürnberg, Erlangen, Germany., Asmus F; Bayer HealthCare Pharmaceuticals, Berlin, Germany; Department of Neurodegeneration, Center of Neurology, University Hospital of Tübingen, and Hertie Institute for Clinical Brain Research, Tübingen, Germany., Zeitz O; Bayer HealthCare Pharmaceuticals, Berlin, Germany; Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany., Ishibashi T; Department of Ophthalmology, Kyushu University, Fukuoka, Japan. Electronic address: ishi@eye.med.kyushu-u.ac.jp.

مؤلفون مشاركون: MYRROR Investigators

المصدر: Ophthalmology [Ophthalmology] 2015 Jun; Vol. 122 (6), pp. 1220-7. Date of Electronic Publication: 2015 Mar 04.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-4713 (Electronic) Linking ISSN: 01616420 NLM ISO Abbreviation: Ophthalmology Subsets: MEDLINE

مواضيع طبية MeSH: Angiogenesis Inhibitors/*therapeutic use , Choroidal Neovascularization/*drug therapy , Myopia, Degenerative/*drug therapy , Receptors, Vascular Endothelial Growth Factor/*therapeutic use , Recombinant Fusion Proteins/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Choroidal Neovascularization/etiology ; Choroidal Neovascularization/physiopathology ; Double-Blind Method ; Female ; Humans ; Intravitreal Injections ; Male ; Middle Aged ; Myopia, Degenerative/complications ; Myopia, Degenerative/physiopathology ; Tomography, Optical Coherence ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity/physiology